Comparative Pharmacology
Head-to-head clinical analysis: POMALYST versus THALIDOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALYST versus THALIDOMIDE.
POMALYST vs THALIDOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
None Documented
None Documented
Clinical Note
moderateThalidomide + Digoxin
"Thalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThalidomide + Digitoxin
"Thalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThalidomide + Deslanoside
"Thalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThalidomide + Acetyldigitoxin
"Thalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Category C
Category D/X
Immunomodulatory Agent
Immunomodulatory Agent